Regeneron director Sing proposes $20.4M share sale

The listed shares include options exercised under a registered plan and options exercised previously.

Available on EDGAR 11/02/2026 - 04:14 PM EST Accepted by SEC EDGAR 11/02/2026 - 04:13 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Regeneron Pharmaceuticals, Inc. (REGN) director George L. Sing filed a notice to sell 21,129 common shares, with an aggregate market value of $20,376,359.76. The notice lists November 2, 2026, as the approximate sale date and names Morgan Stanley Smith Barney LLC as broker.

Key Figures

Common shares reported for sale: 21,129 shares Aggregate market value: $20,376,359.76 Issuer shares outstanding: 101,630,713 shares

3 metrics

Common shares reported for sale 21,129 shares George L. Sing's notice

Aggregate market value $20,376,359.76 Shares reported for sale

Issuer shares outstanding 101,630,713 shares Regeneron Pharmaceuticals, Inc.

Key Terms

Rule 144, Exercise of Options Under a Registered Plan, Previously Exercised Options

3 terms

Rule 144 regulatory

"See the definition of "person" in paragraph (a) of Rule 144."

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

Exercise of Options Under a Registered Plan financial

"Exercise of Options Under a Registered Plan"

Previously Exercised Options financial

"Previously Exercised Options"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many REGN shares did George L. Sing report for sale?

George L. Sing reported 21,129 common shares for sale, with an aggregate market value of $20,376,359.76. The approximate sale date listed is November 2, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001225471
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	REGENERON PHARMACEUTICALS, INC.
SEC File Number	000-19034
Address of Issuer	777 Old Saw Mill River Road Tarrytown NEW YORK 10591-6707
Phone	(914) 847-7000
Name of Person for Whose Account the Securities are To Be Sold	GEORGE L. SING
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Director

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	21129	20376359.76	101630713	11/02/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	11/02/2026	Exercise of Options Under a Registered Plan	Issuer			2610	11/02/2026	Cash
Common	12/30/2025	Previously Exercised Options	Issuer			3024	12/30/2025	Cash
Common	11/02/2026	Exercise of Options Under a Registered Plan	Issuer			2479	11/02/2026	Cash
Common	11/02/2026	Exercise of Options Under a Registered Plan	Issuer			2480	11/02/2026	Cash
Common	01/02/2026	Previously Exercised Options	Issuer			323	01/02/2026	Cash
Common	11/02/2026	Exercise of Options Under a Registered Plan	Issuer			2480	11/02/2026	Cash
Common	05/03/2024	Previously Exercised Options	Issuer			1123	05/03/2024	Cash
Common	11/02/2026	Exercise of Options Under a Registered Plan	Issuer			2610	11/02/2026	Cash
Common	11/02/2026	Exercise of Options Under a Registered Plan	Issuer			2610	11/02/2026	Cash
Common	12/31/2024	Previously Exercised Options	Issuer			1390	12/31/2024	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks
Date of Notice	11/02/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ George L Sing
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)